Human Immunology News Volume 8.45 | Nov 17 2020

May 12, 2022

HIN 8.45 | Nov 17 2020

Human Immunology News by STEMCELL Technologies

Vol. 8.45 – 17 November, 2020

TOP STORY

Mutations
in BRCA1 and BRCA2 Differentially Affect the Tumor Microenvironment and Response to Checkpoint Blockade Immunotherapy

Investigators report differential effects of mutations in the homologous recombination genes BRCA1 and BRCA2 on response to immune checkpoint blockade in mouse and human tumors.
[Nature Cancer]

Abstract

Virtual Conference Exhibition: Immunology

PUBLICATIONSRanked by the impact factor of the journal

Flt3
Ligand Augments Immune Responses to Anti-DEC-205-NY-ESO-1 Vaccine through Expansion of Dendritic Cell Subsets

Researchers evaluated a regimen of Flt3L to increase dendritic cells and other antigen-presenting cells, poly-ICLC and a vaccine comprising anti-DEC-205-NY-ESO-1, a fusion antibody targeting CD205, linked to NY-ESO-1.
[Nature Cancer]

Abstract

Lymphatic
Drainage from Bronchus-Associated Lymphoid Tissue in Tolerant Lung Allografts Promotes Peripheral Tolerance

Investigators showed that tolerant lung allografts could induce and maintain tolerance of heterotopic donor-matched hearts through pathways that were dependent on the continued presence of the transplanted lung.
[Journal of Clinical Investigation]

Full Article

TRPML2 Is an Osmo/Mechanosensitive Cation Channel in Endolysosomal Organelles

Scientists demonstrated the endolysosomal cation channel TRPML2 to be hypotonicity/mechanosensitive, a feature crucial to its involvement in fast-recycling processes of immune cells.
[Science Advances]

Full Article

A
CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy

By assessing resistance to the clinical CD3-bispecific antibody flotetuzumab, researchers identified core fucosylation as a critical pathway to regulate flotetuzumab binding to the CD123 antigen.
[Cancer Immunology Research]

Abstract

PVRIG
Is a Novel NK Cell Immune Checkpoint Receptor in Acute Myeloid Leukemia

Scientists showed that acute myeloid leukemia (AML) patient blasts consistently expressed the poliovirus receptor-related immunoglobulin domain-containing (PVRIG) ligand. Furthermore, PVRIG blockade significantly enhanced NK cell killing of PVRL2⁺, poliovirus receptorlo AML cell lines, and significantly increased NK cell activation and degranulation in the context of patient primary AML blasts.
[Haematologica]

Abstract

LncRNA
and mRNA Expression Profile of Peripheral Blood Mononuclear Cells in Primary Sjögren’s Syndrome Patients

Researchers elucidated the expression profile and the potential role of long non-coding RNA (LncRNA) in the peripheral blood mononuclear cells of primary Sjögren’s syndrome patients.
[Scientific Reports]

Full Article

Characterization of CD4⁺
T-Cell Subtypes Using Single Cell RNA Sequencing and the Impact of Cell Number and Sequencing Depth

Investigators generated a high depth, high cell number dataset to determine the effect of reduced sequencing depth and cell number on the ability to accurately identify CD4⁺ T-cell subtypes.
[Scientific Reports]

Full Article

REVIEWS

Neuroprotective
versus Neuroinflammatory Roles of Complement: From Development to Disease

Complement proteins are ancient components of innate immunity that have emerged as crucial regulators of neural networks. Investigators discuss these roles in the context of the CNS development, acute CNS viral infections, and post-infectious and noninfectious CNS disorders, with an emphasis on microglia-mediated loss of synapses.
[Trends in Neurosciences]

Abstract

INDUSTRY AND POLICY NEWS

Proteintech and HebeCell Announce Collaboration on Nanobody iPSC-derived Natural Killer Cells

Proteintech and HebeCell announced their collaborative partnership to develop proprietary nanobody based chimeric antigen receptor technology for the development and commercialization of iPSC-derived natural killer cells, a promising cellular immunotherapy treatment for cancer and other diseases.
[Proteintech]

Press Release

Innate Pharma Receives Prime Designation from the European Medicines Agency for Lacutamab in Sézary Syndrome

Innate Pharma SA announced that the European Medicines Agency granted PRIME designation to lacutamab, the company’s proprietary first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, for the treatment of patients with relapsed or refractory Sézary syndrome who have received at least two prior systemic therapies.
[Innate Pharma SA]

Press Release

FEATURED EVENT

Mutations
in BRCA1 and BRCA2 Differentially Affect the Tumor Microenvironment and Response to Checkpoint Blockade Immunotherapy

Flt3
Ligand Augments Immune Responses to Anti-DEC-205-NY-ESO-1 Vaccine through Expansion of Dendritic Cell Subsets

Lymphatic
Drainage from Bronchus-Associated Lymphoid Tissue in Tolerant Lung Allografts Promotes Peripheral Tolerance

TRPML2 Is an Osmo/Mechanosensitive Cation Channel in Endolysosomal Organelles

A
CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy

PVRIG
Is a Novel NK Cell Immune Checkpoint Receptor in Acute Myeloid Leukemia

LncRNA
and mRNA Expression Profile of Peripheral Blood Mononuclear Cells in Primary Sjögren’s Syndrome Patients

Characterization of CD4⁺
T-Cell Subtypes Using Single Cell RNA Sequencing and the Impact of Cell Number and Sequencing Depth

Neuroprotective
versus Neuroinflammatory Roles of Complement: From Development to Disease

Proteintech and HebeCell Announce Collaboration on Nanobody iPSC-derived Natural Killer Cells

Innate Pharma Receives Prime Designation from the European Medicines Agency for Lacutamab in Sézary Syndrome

Keystone
Symposia: Innate Immunity: Mechanisms and Modulation

> See All Events

Tier 2 Canada Research Chair – Immunology and Inflammation

Research Group Leader – Immunology and Infection

Senior
Scientific Researcher – Immunology Discovery

PhD Student – Adoptive T Cell Therapy of Cancer

Postdoctoral Fellow – Cancer Immunology and Immunotherapy

> See All Jobs